306 related articles for article (PubMed ID: 38431463)
1. TET2 mutation as prototypic clonal hematopoiesis lesion.
Guarnera L; Jha BK
Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
[TBL] [Abstract][Full Text] [Related]
2. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.
Joshi K; Zhang L; Breslin S J P; Kini AR; Zhang J
J Exp Clin Cancer Res; 2022 Oct; 41(1):294. PubMed ID: 36203205
[TBL] [Abstract][Full Text] [Related]
3. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
[TBL] [Abstract][Full Text] [Related]
4. Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells.
McClatchy J; Strogantsev R; Wolfe E; Lin HY; Mohammadhosseini M; Davis BA; Eden C; Goldman D; Fleming WH; Conley P; Wu G; Cimmino L; Mohammed H; Agarwal A
Nat Commun; 2023 Dec; 14(1):8102. PubMed ID: 38062031
[TBL] [Abstract][Full Text] [Related]
5. TET proteins and 5-methylcytosine oxidation in hematological cancers.
Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
[TBL] [Abstract][Full Text] [Related]
6. Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling.
Caiado F; Kovtonyuk LV; Gonullu NG; Fullin J; Boettcher S; Manz MG
Blood; 2023 Feb; 141(8):886-903. PubMed ID: 36379023
[TBL] [Abstract][Full Text] [Related]
7. TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.
Guan Y; Hasipek M; Tiwari AD; Maciejewski JP; Jha BK
Semin Hematol; 2021 Jan; 58(1):27-34. PubMed ID: 33509440
[TBL] [Abstract][Full Text] [Related]
8. A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions.
Shin TH; Zhou Y; Chen S; Cordes S; Grice MZ; Fan X; Lee BC; Aljanahi AA; Hong SG; Vaughan KL; Mattison JA; Kohama SG; Fabre MA; Uchida N; Demirci S; Corat MAF; Métais JY; Calvo KR; Buscarlet M; Natanson H; McGraw KL; List AF; Busque L; Tisdale JF; Vassiliou GS; Yu KR; Dunbar CE
Blood; 2022 Oct; 140(16):1774-1789. PubMed ID: 35714307
[TBL] [Abstract][Full Text] [Related]
9. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
[No Abstract] [Full Text] [Related]
10. Clonal hematopoiesis and associated diseases: A review of recent findings.
Asada S; Kitamura T
Cancer Sci; 2021 Oct; 112(10):3962-3971. PubMed ID: 34328684
[TBL] [Abstract][Full Text] [Related]
11. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis.
Tulstrup M; Soerensen M; Hansen JW; Gillberg L; Needhamsen M; Kaastrup K; Helin K; Christensen K; Weischenfeldt J; Grønbæk K
Nat Commun; 2021 Oct; 12(1):6061. PubMed ID: 34663818
[TBL] [Abstract][Full Text] [Related]
12. Tet2- and Tet3- Mediated Cytosine Hydroxymethylation in Six2 Progenitor Cells in Mice Is Critical for Nephron Progenitor Differentiation and Nephron Endowment.
Liang X; Aranyi T; Zhou J; Guan Y; Hu H; Liu H; Susztak K
J Am Soc Nephrol; 2023 Apr; 34(4):572-589. PubMed ID: 36522157
[TBL] [Abstract][Full Text] [Related]
13. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.
Busque L; Patel JP; Figueroa ME; Vasanthakumar A; Provost S; Hamilou Z; Mollica L; Li J; Viale A; Heguy A; Hassimi M; Socci N; Bhatt PK; Gonen M; Mason CE; Melnick A; Godley LA; Brennan CW; Abdel-Wahab O; Levine RL
Nat Genet; 2012 Nov; 44(11):1179-81. PubMed ID: 23001125
[TBL] [Abstract][Full Text] [Related]
14. The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia.
Nakauchi Y; Azizi A; Thomas D; Corces MR; Reinisch A; Sharma R; Cruz Hernandez D; Köhnke T; Karigane D; Fan A; Martinez-Krams D; Stafford M; Kaur S; Dutta R; Phan P; Ediriwickrema A; McCarthy E; Ning Y; Phillips T; Ellison CK; Guler GD; Bergamaschi A; Ku CJ; Levy S; Majeti R
Blood Cancer Discov; 2022 Jul; 3(4):346-367. PubMed ID: 35532363
[TBL] [Abstract][Full Text] [Related]
15. Clonal Hematopoiesis of Indeterminate Potential With Loss of
Lin AE; Bapat AC; Xiao L; Niroula A; Ye J; Wong WJ; Agrawal M; Farady CJ; Boettcher A; Hergott CB; McConkey M; Flores-Bringas P; Shkolnik V; Bick AG; Milan D; Natarajan P; Libby P; Ellinor PT; Ebert BL
Circulation; 2024 Apr; 149(18):1419-1434. PubMed ID: 38357791
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of TET2 in hematologic malignancies.
Chiba S
Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
[TBL] [Abstract][Full Text] [Related]
17. Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease.
Cobo I; Tanaka T; Glass CK; Yeang C
Curr Opin Hematol; 2022 Jan; 29(1):1-7. PubMed ID: 34654019
[TBL] [Abstract][Full Text] [Related]
18. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Nakajima H; Kunimoto H
Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
[TBL] [Abstract][Full Text] [Related]
19. Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.
Schiroli G; Kartha V; Duarte FM; Kristiansen TA; Mayerhofer C; Shrestha R; Earl A; Hu Y; Tay T; Rhee C; Buenrostro JD; Scadden DT
Nat Commun; 2024 May; 15(1):4325. PubMed ID: 38773071
[TBL] [Abstract][Full Text] [Related]
20. Clonal hematopoiesis: mechanisms driving dominance of stem cell clones.
Challen GA; Goodell MA
Blood; 2020 Oct; 136(14):1590-1598. PubMed ID: 32746453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
